New triple therapy shows promise in shrinking advanced stomach tumors before surgery

NCT ID NCT06461910

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an immune-boosting drug (thymalfasin) to standard chemotherapy and immunotherapy can help shrink stage III stomach or gastroesophageal junction cancer before surgery. About 30 adults aged 18-75 will receive the combination, then have their tumor tissue examined after surgery to see if all cancer cells are gone. The goal is to improve the chance of complete removal and long-term control of the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact